IRLAB Therapeutics (IRLAB A.ST) Osake Kurssi

IRLAB Therapeutics AB is primarily active in the pharmaceutical industry.

The main competitors of IRLAB Therapeutics AB in the market are pharmaceutical companies that focus on developing therapeutics for neurological disorders and Parkinson's disease. Some notable competitors include Biogen Inc., Acorda Therapeutics Inc., and Adamas Pharmaceuticals Inc. These companies also strive to provide innovative treatment options for patients suffering from similar conditions. IRLAB Therapeutics AB differentiates itself by its unique investigational drug, IRL790, which has shown promising results in clinical trials for Parkinson's disease treatment.

IRLAB Therapeutics AB is a pharmaceutical company based in Sweden. It was founded in 2012 with a focus on developing innovative treatments for neurodegenerative diseases and Parkinson's disease. IRLAB Therapeutics AB is dedicated to improving the quality of life for patients affected by these conditions. The company's research and development efforts are centered around exploring new drug candidates and therapeutic solutions. IRLAB Therapeutics AB aims to address the unmet medical needs in neurology and create effective medications that can significantly impact patients' lives. With a strong commitment to scientific excellence, IRLAB Therapeutics AB is actively pursuing advancements in the field of neurodegenerative diseases.

IRLAB Therapeutics AB has achieved several significant milestones in its corporate journey. In recent years, the company has made remarkable progress in the field of neurological disorders. IRLAB successfully completed a Phase 2b study for its candidate, IRL752, intended for the treatment of Parkinson's disease psychosis. The positive results demonstrated the drug's potential in addressing this challenging condition. Additionally, IRLAB advanced its Phase 2a study for IRL790, a drug candidate targeting Parkinson's disease symptoms, such as abnormal involuntary movements. The company's commitment to innovative therapies and dedication to improving patients' lives showcases IRLAB Therapeutics AB as a leading player in the neurology sector.

IRLAB Therapeutics AB is primarily present in Sweden, where it is headquartered.

IRLAB Therapeutics AB is dedicated to improving the lives of patients suffering from neurological disorders. The company focuses on developing innovative pharmaceuticals that target unmet medical needs, particularly within the field of Parkinson's disease. IRLAB Therapeutics AB's core values include a commitment to scientific excellence, collaboration, and a patient-centered approach. By combining cutting-edge research with a deep understanding of the complexities of neurological disorders, IRLAB Therapeutics AB strives to bring transformative treatments to market and make a positive impact on the lives of those affected by these conditions.

Nykyisellä valuuttakurssilla IRLAB Therapeutics-osake noteerataan hintaan 0,16 EUR (1,84 SEK).

IRLAB Therapeutics-osake (IRLAB A.ST) on listattuna 3 pörssissä, muun muassa: Frankfurt (6IRA.F), Stockholm (IRLAB A.ST).

IRLAB Therapeutics AB is a biopharmaceutical company based in Sweden that specializes in the discovery and development of innovative drugs for neurodegenerative diseases and pain. Its business model is based on the identification of new compounds, preclinical evaluation, and conducting clinical studies to demonstrate their effectiveness and safety. IRLAB's vision is to help patients achieve a better quality of life by developing drugs that are effective in treating diseases such as Parkinson's, Huntington's, Alzheimer's, and pain. The company's research and development activities are divided into different business areas, including academic research and pharmaceutical development. IRLAB's academic research involves collaborating with renowned academic institutions, universities, and private laboratories worldwide. The company is also involved in researching new technologies and methods to develop better drugs and accelerate the process. On the pharmaceutical development level, IRLAB focuses on two main categories of compounds. On one hand, they are developing selective dopamine concentration modifiers (SDMs) that can improve the function of dopamine neurons in Parkinson's patients. On the other hand, they are developing selective catechol-O-methyltransferase inhibitors (COMT inhibitors) that can be used in the treatment of Parkinson's. The company has also developed a pipeline of drugs for Huntington's disease and pain, which are in various stages of clinical development. IRLAB works closely with medical experts and patient groups to ensure that their drugs meet patient needs. Additionally, the company has entered into a licensing agreement for the commercialization of an already approved product for psychiatric disorders. This product, called IRLAB technology, is for the long-term treatment of panic disorders and generalized anxiety disorders. IRLAB's business model also includes strong partnerships with other pharmaceutical companies and institutional investors to mobilize capital for research and development. The company has entered into several partnerships with other companies to advance the development and commercialization of its products. Overall, IRLAB Therapeutics AB's business model is based on developing innovative drugs for serious neurodegenerative diseases and pain. Through collaboration with leading academics and partners, the company has built a strong pipeline of drugs aiming to help patients achieve a better quality of life. IRLAB is committed to continuous exploration of new technologies and methods to improve the drug development process and better meet the needs of patients.

odotettu liikevaihto IRLAB Therapeutics on 101,20 M SEK. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto IRLAB Therapeutics on −173,00 M SEK. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

IRLAB Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,87. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan IRLAB Therapeutics-osakkeen arvostusta.

IRLAB Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,49. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii IRLAB Therapeutics-osakkeen arvostuskennuslukuna.

IRLAB Therapeutics:n Eulpool-laatuscore on 2/10.

IRLAB Therapeutics:n ISIN on SE0012675361. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

IRLAB Therapeutics:n WKN on A2PLBE. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

IRLAB Therapeutics:n ticker on IRLAB A.ST. Tämä pörssinoteeraus käytetään IRLAB Therapeutics-osakkeiden kauppaan pörssissä.